The Cancer Letter

Inside information on cancer research and drug development

In Brief

CPRIT Oversight Committee approves $89M in grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Oversight Committee of the Cancer Prevention and Research Institute of Texas, approved a large slate of awards totaling over $89 million for cancer research, prevention and product development. The list of grants is included below.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

CPRIT awards $67M in research grants to Texas institutions

The governing body of the Cancer Prevention and Research Institute of Texas approved 53 grants totaling more than $67 million to state research institutions to advance the state’s fight against cancer. The grants provide funding for a wide array of cancer projects, including CPRIT Scholar recruitment awards, funding for collaborative core facilities, and support for cancer clinical trials.
In Brief

Kristen Doyle named CEO of CPRIT

Kristen Doyle was approved by the governing body of the Cancer Prevention and Research Institute of Texas as the agency’s new CEO beginning July 1. Doyle, currently deputy executive officer and general counsel, will succeed Wayne Roberts who will step down on June 30 after 12 years as chief executive.
In Brief

CPRIT approves nearly $99M in grants

The governing body of the Cancer Prevention and Research Institute of Texas, or CPRIT, approved $98,592,155 in grants to focus on cancer in Texas. The grants are a mix of academic research and prevention projects and represents the largest public state commitment to cancer research by any U.S. state.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account